申请人:Boehringer Ingelheim International GmbH
公开号:EP1598353A1
公开(公告)日:2005-11-23
The invention relates to pyrrolobenzimidazolone compounds of formula (I),
wherein A,T and R1 to R3 are defined as in claim 1, which possess tubulin inhibitory activity and are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation and the use thereof for preparing a pharmaceutical composition.
该发明涉及式(I)的吡咯苯并咪唑酮化合物,其中A、T和R1至R3的定义如权利要求书中所述,具有微管抑制活性,适用于治疗由细胞过度或异常增殖所特征的疾病,并用于制备药物组合物。